TCT 2024 - TCTMD.com
Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
TCTMD - tctmd.com
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
What’s Going to Be Big at TCT 2024? | tctmd.com
Oct 17, 2024 · TCT 2024, the annual scientific showcase of interventional cardiovascular medicine, is returning once again to Washington, DC. The 4-day meeting starts Sunday, October 27, 2024, and will involve more than 1,400 faculty spread out across 161 different sessions, including 33 live endovascular, structural, and coronary cases. Three sessions, one per day, will deliver 11 late-breaking clinical ...
Cheaper Version of Tirzepatide for Weight Loss Now Available, …
Aug 28, 2024 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply.
AHA 2024 | tctmd.com
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity
Oct 1, 2024 · Once-weekly semaglutide (Wegovy; Novo Nordisk) improves outcomes in patients who have obesity-related heart failure with preserved ejection fraction (HFpEF) across subgroups defined by baseline 6-minute walk distance and frailty status, according to two prespecified analyses of the STEP-HFpEF program.
SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity
Nov 16, 2024 · CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with obesity and heart failure with preserved ejection (HFpEF), results of the SUMMIT trial show.
SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients
Oct 23, 2024 · An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular events than traditional therapy alone in patients with diabetes and established CVD and/or chronic kidney disease (CKD), …
ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty …
Oct 29, 2024 · Interventional cardiologists have many tools at their fingertips to address calcified lesions—which are known to be among the most complex—including angioplasty with conventional balloons as well as cutting and scoring balloons, orbital and rotational atherectomy, and lithotripsy. These new data indicate that the simplest—and notably the cheapest—approach might be the most reasonable.
SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide ...
Aug 1, 2024 · Patients who have heart failure with preserved ejection fraction (HFpEF) and obesity can be safely and effectively treated with tirzepatide (Mounjaro and Zepbound; Eli Lilly) through 2 years of follow-up, with topline data from the phase III SUMMIT trial showing the drug reduces heart failure events and improves other patient …